.Nature Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ sophisticated bosom cancer as well as energetic or steady mind metastases presented constant intracranial activity as well as wide spread efficiency of T-DXd.